Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Net Margin (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Net Margin for 11 consecutive years, with 6549.66% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin rose 1042615.0% to 6549.66% in Q3 2025 year-over-year; TTM through Dec 2025 was 34863.5%, a 3475529.0% decrease, with the full-year FY2025 number at 32573.75%, down 3237143.0% from a year prior.
  • Net Margin was 6549.66% for Q3 2025 at Cartesian Therapeutics, up from 7614.43% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 6549.66% in Q3 2025 to a low of 7614.43% in Q2 2025.
  • A 5-year average of 437.58% and a median of 71.1% in 2021 define the central range for Net Margin.
  • Biggest YoY gain for Net Margin was 1042615bps in 2025; the steepest drop was -764337bps in 2025.
  • Cartesian Therapeutics' Net Margin stood at 41.34% in 2021, then decreased by -15bps to 35.09% in 2022, then crashed by -1320bps to 428.16% in 2023, then skyrocketed by 778bps to 2903.95% in 2024, then skyrocketed by 126bps to 6549.66% in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Net Margin are 6549.66% (Q3 2025), 7614.43% (Q2 2025), and 4968.5% (Q1 2025).